Anxiolytic Peptide · Non-Sedating

Selank: Russian Anxiolytic Heptapeptide

A UK-focused, evidence-based comparison of Selank and Dihexa — mechanism, benefits, dosing, side effects, legal status, and stacking.

Selank is a synthetic heptapeptide developed in the 1990s by the same Russian Institute of Molecular Genetics that created Semax, designed as a longer-acting analogue of the endogenous tetrapeptide tuftsin. Sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro. It is registered as a prescription anxiolytic in Russia and Ukraine under the brand name Selank for generalised anxiety disorder and neurasthenia. Unlike benzodiazepines, Selank produces calm without sedation, without dependence, and without cognitive blunting — a profile that has made it a long-standing favourite in the international nootropic community for users seeking anxiety reduction without the impairment trade-offs of GABAergic drugs.

What is Selank?

Selank (also written Selanc, Selantin) is a heptapeptide combining the tuftsin sequence (Thr-Lys-Pro-Arg) with the C-terminal stabilising tripeptide Pro-Gly-Pro borrowed from Semax. The Pro-Gly-Pro tail resists peptidase degradation, allowing meaningful CNS penetration when delivered intranasally through the cribriform plate. It is the product of the same Ashmarin laboratory that originated Semax. In Russia Selank is approved for generalised anxiety disorder, neurasthenia, and adjustment disorders, with around 30-40 published peer-reviewed papers including Russian Phase 3 trials. The N-acetyl variant (N-Acetyl Selank) is also sold by research-chemical suppliers and follows the same logic as N-Acetyl Semax — longer per-dose duration without changing receptor pharmacology.

Chemistry: Thr-Lys-Pro-Arg-Pro-Gly-Pro · MW 751.86 g/mol · Tuftsin analogue
Origin: Institute of Molecular Genetics, Russian Academy of Sciences (1990s)
Primary route: Intranasal spray (primary)
Pharmacokinetics: CNS half-life is brief (minutes) but anxiolytic effects persist 4-6 hours; BDNF upregulation persists 24h+.
Class: Russian peptide · Tuftsin analogue

Mechanism of Action

Selank engages a multi-target anxiolytic mechanism distinct from benzodiazepines. The headline effects are: modulation of GABAergic transmission indirectly (without direct GABA-A receptor binding, avoiding benzodiazepine-style tolerance and dependence); upregulation of BDNF mRNA in the hippocampus, similar in magnitude to Semax (Inozemtseva et al., 2008); modulation of monoamine balance in cortical and limbic regions; and a documented immunomodulatory profile via the tuftsin parent sequence (enhancing macrophage and natural killer cell function). Selank also produces measurable changes in plasma enkephalin levels and modulates the limbic-hypothalamic-pituitary-adrenal axis under stress. Crucially, it does not bind GABA-A or any classic anxiolytic target directly — its effect emerges from broader neurochemical and trophic-factor rebalancing, which is why withdrawal and dependence are not observed.

Proposed Benefits

The clearest and most replicated effect is anxiety reduction within 20-40 minutes of intranasal dosing, without the sedation, ataxia, or cognitive blunting associated with benzodiazepines. Users frequently report a sense of "lifted weight" and reduced rumination, with preserved alertness and verbal fluency — a useful profile for high-functioning anxiety or pre-performance settings. Other reported benefits include mood lift over 7-14 day courses, improved stress resilience, mild cognitive sharpening (likely BDNF-mediated and overlapping with Semax), better sleep quality without daytime sedation, and immunomodulation reported in Russian respiratory infection trials. In Russian clinical practice Selank is used for generalised anxiety disorder, adjustment disorder following stress, neurasthenia, and as an adjunct in some depression protocols. The compound does not produce intoxication and is not a recreational target.

Evidence Base

The Selank evidence base is smaller than Semax but methodologically reasonable for a Russian peptide. Key studies: Zozulya et al. 2008 (randomised double-blind comparison vs medazepam in GAD, n=62, equivalent efficacy with no sedation/dependence), Vyunova et al. 2018 (BDNF effects), Inozemtseva et al. 2008 (BDNF mRNA expression), Uchakina et al. 2008 (immune effects), and various Russian Phase 3 GAD registrations. Western replication is minimal. The Zozulya GAD trial is the strongest piece of evidence and broadly supports parity with medazepam for anxiety symptoms with a cleaner side-effect profile. No published trial in healthy enhancement-seeking populations exists, no head-to-head against SSRIs or SNRIs, and no long-term safety study at nootropic doses.

Dosage & Administration

No medically approved dose exists outside Russia. The Russian 0.15% spray is dosed at 2-3 drops in each nostril, 2-3 times daily, for 7-14 days as an anxiolytic course (~450-1800 µg/day). Community nootropic protocols use lyophilised research-grade vials reconstituted to deliver 250-600 µg intranasally 1-2 times per day, cycled for 14 days on then 7+ days off. Bioavailability via the intranasal route is well above 50% to CNS. N-Acetyl Selank, with its extended half-life, is usually dosed once per day at the same total milligram amount. Tilt head back, dose into each nostril without sniffing hard. Subcutaneous injection is sometimes reported but does not appear to offer advantage over intranasal for CNS targets.

This is a community-reported protocol summary, not a medical recommendation. There is no established human dose. Consult a qualified healthcare professional before using any research compound.

Side Effects & Risks

Selank has an exceptionally clean acute safety profile across the published literature. Reported issues are rare and mild: occasional nasal irritation (saline vehicle), brief headache in the first 1-2 doses, very rarely mild euphoria or anxiolysis stronger than desired (typically dose-related, resolves within hours), and very rare transient taste disturbance. The 2008 Zozulya double-blind GAD trial reported no statistically significant difference in adverse events between Selank and placebo. Unlike benzodiazepines, Selank does not cause sedation, ataxia, cognitive impairment, dependence, or withdrawal. Contraindications: pregnancy/breastfeeding (no safety data), known peptide hypersensitivity. There is no documented interaction profile with common psychiatric medications, but caution applies to any combination with active anxiolytics, hypnotics, or psychotropics.

UK Legal Status

In the United Kingdom Selank is not a controlled substance under the Misuse of Drugs Act 1971, not licensed as a medicine by the MHRA, and not scheduled under the Psychoactive Substances Act 2016. It is legal to purchase and possess as a research chemical for laboratory use; it cannot be lawfully sold for human consumption. WADA does not list Selank on the Prohibited List as of the 2026 update. The compound is sold in Russia and Ukraine as a registered prescription medicine. US status is restrictive — the FDA does not recognise Selank as a dietary supplement and treats it as an unapproved drug for human use.

Selank vs Dihexa

Selank and Dihexa address fundamentally different goals. Selank is an anxiolytic peptide producing calm and stress resilience without sedation or cognitive impairment; its mechanism is indirect GABAergic modulation plus BDNF upregulation plus immunomodulation. Dihexa is a cognitive enhancer / synaptogenic peptide acting via HGF/c-Met activation to drive structural dendritic spine formation. The two compounds are mechanistically distinct and operationally complementary: Selank for emotional regulation, Dihexa for cognitive structural reinforcement. They do not compete for the same receptor system. Route differs: Selank is intranasal, Dihexa is orally bioavailable (~38%). Time course differs: Selank is acutely felt at 20-40 min and sustains for 4-6 hours per dose; Dihexa's synaptogenic effects build over weeks and persist after the molecule clears.

Stacking with Dihexa

Selank pairs naturally with cognitive-enhancing peptides for users who experience anxiety as a limiting factor in mental performance. The classic Semax + Selank combination is the most-stacked Russian peptide pair, balancing acute focus and trophic upregulation (Semax) with anxiolysis and stress buffering (Selank). With Dihexa, the rationale is similar — Dihexa provides structural cognitive reinforcement, Selank removes anxiety-driven performance interference. Other reported stacks include Selank + L-theanine for calm focus, Selank + Ashwagandha for HPA-axis support, and Selank + magnesium glycinate at night for sleep quality. There is no published interaction data between Selank and Dihexa specifically, but the mechanisms are non-overlapping. Caution: avoid combining with benzodiazepines (theoretical additive effect, no data), and approach SSRI/SNRI combinations with awareness that monoamine modulation could compound.

Frequently Asked Questions

Selank does not produce dependence or withdrawal in the published Russian literature or in clinical use. Unlike benzodiazepines it does not bind GABA-A directly, which is the mechanism most responsible for benzodiazepine tolerance and dependence.

In the Zozulya 2008 double-blind trial Selank produced anxiolytic effects comparable to medazepam without the sedation, cognitive impairment, or dependence profile. Subjectively, Selank feels less "blunting" and preserves verbal fluency and alertness.

There is no documented adverse interaction, but no formal safety data either. Both modulate monoamine balance so a cautious approach (lower starting doses, monitoring) is appropriate. Discuss with a healthcare professional.

Yes, as a research chemical for laboratory use. It is not a controlled substance, not scheduled under the Psychoactive Substances Act, and not licensed as a medicine by the MHRA.

Acute anxiolytic effects are typically felt within 20-40 minutes of an intranasal dose. Cumulative mood and resilience benefits build over 7-14 days of consistent dosing.

The acetylated version of Selank, with an acetyl group on the N-terminal threonine to resist degradation. Same receptor pharmacology, longer per-dose duration. Often more convenient as a once-daily dose.

The Bottom Line

Selank is the best-validated anxiolytic peptide in the Russian nootropic tradition, offering benzodiazepine-like anxiety reduction without the sedation, dependence, or cognitive impairment that limit traditional anxiolytics. Mechanistically it does not overlap with Dihexa — Selank addresses emotional regulation and stress buffering, Dihexa addresses cognitive structural plasticity — making the two complementary rather than competitive. For users whose cognitive performance is bottlenecked by anxiety or stress, Selank is the most evidence-supported peptide solution.